Molecular Partners Valuation
| MOLN Stock | USD 5.23 0.01 0.19% |
At this time, the firm appears to be undervalued. Molecular Partners secures a last-minute Real Value of $6.31 per share. The latest price of the firm is $5.23. Our model forecasts the value of Molecular Partners from analyzing the firm fundamentals such as Return On Equity of -0.37, operating margin of (21.42) %, and Shares Outstanding of 36.86 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Molecular Partners' valuation include:
Price Book 1.2563 | Enterprise Value | Enterprise Value Ebitda 1.2347 | Price Sales 32.1216 | Forward PE 1.7775 |
Undervalued
Today
Please note that Molecular Partners' price fluctuation is slightly risky at this time. Calculation of the real value of Molecular Partners is based on 3 months time horizon. Increasing Molecular Partners' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Molecular Partners is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Molecular Stock. However, Molecular Partners' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.23 | Real 6.31 | Target 10.26 | Hype 5.22 | Naive 5.04 |
The intrinsic value of Molecular Partners' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Molecular Partners' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Molecular Partners AG helps investors to forecast how Molecular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Molecular Partners more accurately as focusing exclusively on Molecular Partners' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Molecular Partners' intrinsic value based on its ongoing forecasts of Molecular Partners' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Molecular Partners' closest peers.
Molecular Partners Cash |
|
Molecular Valuation Trend
Knowing Molecular Partners' actual value is paramount for traders when making sound investment determinations. Using both Molecular Partners' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Molecular Partners Total Value Analysis
Molecular Partners AG is now expected to have valuation of 34.59 M with market capitalization of 192.79 M, debt of 3.65 M, and cash on hands of 267.13 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Molecular Partners fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
34.59 M | 192.79 M | 3.65 M | 267.13 M |
Molecular Partners Investor Information
The company has price-to-book ratio of 1.26. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 2.09. The entity had not issued any dividends in recent years. Based on the key indicators related to Molecular Partners' liquidity, profitability, solvency, and operating efficiency, Molecular Partners AG is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Molecular Partners Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Molecular Partners has an asset utilization ratio of 3.55 percent. This suggests that the Company is making $0.0355 for each dollar of assets. An increasing asset utilization means that Molecular Partners AG is more efficient with each dollar of assets it utilizes for everyday operations.Molecular Partners Ownership Allocation
Molecular Partners maintains a total of 36.86 Million outstanding shares. Roughly 94.7 % of Molecular Partners outstanding shares are held by general public with 5.3 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Molecular Partners Profitability Analysis
The company reported the previous year's revenue of 7.04 M. Net Loss for the year was (61.98 M) with loss before overhead, payroll, taxes, and interest of (43.96 M).About Molecular Partners Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Molecular Partners AG. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Molecular Partners based exclusively on its fundamental and basic technical indicators. By analyzing Molecular Partners's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Molecular Partners's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Molecular Partners. We calculate exposure to Molecular Partners's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Molecular Partners's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -36.7 M | -34.9 M | |
| Pretax Profit Margin | (10.13) | (9.62) | |
| Operating Profit Margin | (9.98) | (9.49) | |
| Net Loss | (10.13) | (9.62) | |
| Gross Profit Margin | (6.67) | (6.33) |
Molecular Partners Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 32.8 M | |
| Forward Price Earnings | 1.7775 |
Molecular Partners Current Valuation Indicators
Molecular Partners' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Molecular Partners' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Molecular Partners, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Molecular Partners' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Molecular Partners' worth.When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share | Quarterly Revenue Growth (0.73) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.